A major Nature Medicine study analyzing nearly six million people across 118 countries reveals women are 83% more likely to report facial pain and 74% more likely to suffer headaches. High-intensity pain peaks around age 50, while generalized pain prevalence reaches its highest point at age 70.

University of Washington scientists are preparing to request FDA permission to begin human trials for a new vaccine designed to prevent fentanyl overdoses. The vaccine trains the immune system to produce antibodies that bind to fentanyl molecules, preventing them from entering the brain, with protection potentially lasting up to one year.

Medical teams from Shenzhen and Hong Kong successfully performed an in-utero procedure to remove a fast-growing chest tumour from an unborn child. The operation utilized a novel needle-based technique that vibrates water molecules to generate heat, destroying the tumour tissue while preserving the pregnancy.

The 2026 Nobel Prize in physiology or medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagal at the Karolinska Institute. The committee honored their foundational discoveries regarding light-gated ion channels, which enable optogenetics to control neural activity with light. Awards will be presented in Stockholm on December 10.

The Nobel Committee will announce the 2026 winner in physiology or medicine on Monday morning. Live coverage begins at 5:15 a.m. EDT. Previous recipients included researchers who elucidated mechanisms controlling the immune system and preventing autoimmune disorders.

Johns Hopkins researchers found that lower spine bone density correlates with accelerated white matter degradation and cognitive decline. This link between skeletal health and neural integrity suggests routine chest CT scans could potentially flag dementia risks earlier than traditional brain MRIs.

Rice University researchers created an implantable 'living pharmacy' that produces therapeutic antibodies inside the body for up to one year. The system uses engineered cells in biomaterials to deliver monoclonal antibodies for oncology and autoimmune diseases, allowing for dose adjustment or cessation via minimally invasive replacement.

New data from Epic Research indicates shingles cases are declining among adults aged 34 and younger in the US. Researchers attribute this trend to the widespread use of the chickenpox vaccine since 1995, which reduces the risk of the virus reactivating later in life.

The journal Science published a special issue dedicated to women's health, edited by an all-female team citing political attacks and funding cuts as motives. The issue features reviews on sex-dependent biological differences beyond reproduction, menopause, and the pregnant body.

A Lancet Global Health study estimates chewing tobacco contributed to 251,000 deaths worldwide in 2023. South Asia bears the brunt with 84% of fatalities, primarily from stroke and oral cancers. More than 90% of male deaths occur in ten countries including India and the US.

Vanda Pharmaceuticals announced that its drug HETLIOZ successfully met primary endpoints in a Phase III trial for Delayed Sleep-Wake Phase Disorder. The study showed the drug shifted sleep onset by over 37 minutes compared to placebo. Vanda plans to submit a supplemental New Drug Application to the FDA for this indication.

Preliminary research presented at a European medical meeting links high intake of the sugar Neu5Gc found in red meat to a 63% higher risk of type 2 diabetes. The observational study analyzed data from nearly 90,000 adults, finding the link significant even after adjusting for lifestyle factors.

Scientists in Brisbane have successfully cultivated blood in a laboratory setting, marking a significant medical advancement. This breakthrough offers new hope for families dealing with rare blood types by potentially providing a reliable source of compatible blood products outside of traditional donation methods.

A new IARC study reveals that 12 percent of global cancer cases in 2024 were caused by infections, with H. pylori and HPV being the primary drivers. Low- and middle-income countries bear nearly three-quarters of this burden, prompting authors to recommend scaling up existing vaccines and developing new ones for agents like Epstein-Barr virus.

The 2026 World Alzheimer Report declares the disease is no longer untreatable, marking a shift toward prevention. Co-authored by Alzheimer's Disease International, it highlights an era of unprecedented activity driven by drugs like donanemab and lecanemab that modestly slow early decline.

Researchers at Oregon Health & Science University report that a new blood test capable of detecting more than 50 cancer types is showing positive results in clinical trials. The diagnostic tool could potentially become available to the public next year if development continues successfully.

A University of Surrey study analyzing over 45,000 UK Biobank participants found that sugar exposure in the first 1,000 days increases anxiety risk in adulthood. Researchers noted that avoiding significant sugar intake during pregnancy and early childhood correlates with lower anxiety levels later in life.

Adelaide University researchers analyzed extensive data to conclude that low-intensity exercise reduces acute and chronic pain as effectively as common medications. Programs lasting under 120 minutes weekly were most effective, offering a holistic alternative to pharmaceutical interventions.

A phase 3 clinical trial published in the Journal of the American Medical Association shows that Loberamisal extends the emergency stroke treatment window from six hours to two days. The study found that 70% of patients treated within 48 hours regained complete functional independence, marking a significant improvement over standard care protocols.

The World Health Organization released new guidelines on Wednesday to broaden access to safe and effective contraceptive methods. The recommendations include extended usage periods for oral pills and implants, plus the addition of mifepristone for emergency contraception.

An FDA advisory committee is voting today on whether to recommend approval of Grail's Galleri multi-cancer blood test. Staff documents indicate the panel must determine if the test detects enough early-stage cancers to justify marketing for early detection despite potential false alarms and costly follow-up diagnostics.

A comprehensive meta-analysis published in Family Medicine and Community Health indicates that consuming an extra 100 grams of ultra-processed foods daily increases cardiovascular event risk by 14%. The review of 51 studies covering millions of participants also highlighted significant links to metabolic syndrome, cancer, and mortality.

Roche reported positive interim phase III data showing sefaxersen significantly reduces proteinuria in patients with IgA nephropathy compared to placebo. The IMAgINATION study met its primary endpoint, demonstrating clinically meaningful improvements in urine protein-to-creatinine ratio with the once-monthly injection. The successful trial outcome paves the way for regulatory approval.

Over 200 lawsuits claim GLP-1 weight-loss drugs cause blindness via NAION, prompting manufacturers Novo Nordisk and Eli Lilly to defend their products. The FDA is investigating the potential link but does not currently require warning labels, while several countries outside the U.S. already mandate such disclosures.

University of Washington scientists are preparing to request FDA permission to begin human trials for a novel fentanyl vaccine. Early animal studies suggest the treatment could block the drug's effects for up to a year by triggering antibody production, marking a significant step in combating opioid dependency.

A new study published in PLoS Medicine links increased REM sleep duration to a lower risk of 83 diseases, including dementia and heart failure. Researchers analyzing UK Biobank data also found that greater deep sleep duration correlates with reduced risks for type 2 diabetes and major depressive disorder.

The World Health Organization projects a global deficit of 11.1 million health workers by 2030, with 67 countries unable to maintain current medical standards. Higher-income nations, particularly in Europe, face severe impacts as one in three doctors retires within a decade, intensifying reliance on foreign labor.

The US FDA has approved Ultragenyx Pharmaceutical's Fayuvi gene therapy for treating Sanfilippo syndrome type A in children, marking the first treatment to alter the disease's course rather than just manage symptoms. This approval marks Ultragenyx's second gene therapy approval and sixth overall, accompanied by a priority review voucher.

A major study published in JAMA Network Open links the widely used antibiotic cefepime to a higher risk of all-cause mortality in adults, with a 94.4% probability of association. Researchers analyzed over 22,000 patients but did not recommend discontinuing the drug, citing potential neurotoxicity or dosing issues as factors.

Massachusetts Governor Maura Healey announced new actions to strengthen postpartum care, proposing $2 million for the Welcome Family program. The initiative aims to cover all families welcoming new babies among the approximately 68,000 newborns born annually in the state. Healey previously signed a maternal health law in 2024 expanding access to doulas.

Johnson & Johnson reported its experimental treatment PIPE-307 missed its primary endpoint in the phase 2 MOONLIGHT-1 trial for major depressive disorder. This marks the second mid-stage setback for the molecule. Contineum Therapeutics shares fell 10% as the company shifts focus to its lung-disease program, PIPE-791.

National University of Singapore researchers report that magnetic pulses can reprogram immune cells to attack breast cancer in pre-clinical trials. The technique eradicated tumors in 75 percent of models by triggering cellular changes, offering a potential non-chemotherapy treatment avenue currently under translation development.

New research associates prenatal acetaminophen exposure with smaller ovarian and uterine volumes in female infants, though authors stress it does not establish causation. The study analyzed urine samples from 302 mothers, noting none exceeded recommended daily limits, and found lower Anti-Muellerian hormone concentrations in those exposed before 17 weeks gestation.

An international analysis of 43 studies involving over 48 million people estimates that Helicobacter pylori exposure accounts for 22% of bowel cancer cases globally. The bacteria increases risk by 1.59 times, though antibiotic eradication benefits may take a decade to manifest.

A major UK study of nearly one million adults finds that drinking beverages above 65C triples the risk of oesophageal cancer. Consuming six or more very hot drinks daily further elevates this risk, according to research published in the International Journal of Cancer.

Novartis announced its Phase III HARBOR study for del-desiran failed to meet primary endpoints in treating myotonic dystrophy type 1. The setback wiped approximately US$29.6 billion off the company's market value, compounding recent pipeline failures and increasing pressure on CEO Vas Narasimhan's strategy.

Inhibrx announced positive results for its OX40-targeting immunotherapy INBRX-106, showing a 48% confirmed objective response rate compared to 27% for pembrolizumab alone. Median progression-free survival was 9.6 months for the combination therapy versus 4.9 months for the control arm. Shares rose in premarket trading after the experimental therapy outperformed Merck's Keytruda in head and neck cancer data.

AstraZeneca announced strong Phase 3 trial results for its experimental drug tozorakimab, which reduced dangerous COPD exacerbations by approximately 30%. Data presented in Barcelona and published in the New England Journal of Medicine suggests the treatment could capture a significant market segment among patients ineligible for existing therapies. The company expects multibillion-dollar sales.

The Surrey and Borders Partnership NHS Foundation Trust is screening the first European participants for the phase III PrevenTRON trial. The study tests Roche's Trontinemab on healthy adults aged 55 to 80 with elevated p-tau217 biomarkers, aiming to prevent cognitive decline by targeting amyloid plaques in a global cohort of approximately 1,600 people.

The US Food and Drug Administration has granted clearance to C2N Diagnostics' PrecivityAD2 blood test, marking the first such authorization for symptomatic adults aged 40 and older. The test detects amyloid plaques to aid clinical diagnosis but is not a standalone screening tool.

The US FDA approved Ionis Pharmaceuticals' zanvestro as the first treatment for Alexander disease. The drug targets the underlying mechanism by reducing abnormal GFAP protein production. Ionis plans to independently commercialize it in the U.S., with analysts estimating peak annual sales of approximately $295 million.

Doctors at Mass General Brigham report that a genetically engineered pig kidney sustained patient Tim Andrews for 285 days, breaking the previous longevity record. Andrews lived with the organ for 271 days off dialysis before receiving a donor human kidney, marking the longest dialysis-free survival and first transition from pig-to-human transplantation.

Four major US medical groups issued new vaccine guidelines, including an RSV window extension for pregnant people through March. Developed with the University of Minnesota's Vaccine Integrity Project due to a CDC collaboration breakdown, these recommendations urge broader immunization amid frozen federal advice following ACIP restructuring.

A massive analysis of 2.5 million individuals published in Nature Medicine reveals that fibromyalgia is largely driven by neurological genes. This finding provides indisputable biological evidence for the disorder, which causes widespread pain and fatigue in millions of Americans, countering historical views that it was purely psychological.

The NHS-trialled Galeas at-home urine test identified 92.2% of bladder cancer cases in a study of nearly 1,000 patients. Researchers estimate it could reduce urgent cystoscopies by 730 per 1,000 patients, significantly easing the burden on UK urology departments where approximately 10,900 new cases are diagnosed annually.

Former nurse Pearl Roche died in June at age 73 after her family could not obtain Galantamine due to national supply shortages. Local pharmacies reported severe stock deficits, prompting the Department of Health to acknowledge intermittent availability issues for the medication that significantly improved her quality of life.

Novartis shares rose 4.5% in European trading Tuesday after reporting positive late-stage trial results for a multiple sclerosis pill. The drug demonstrated significant reduction in annualized relapse rates and superiority on key secondary endpoints versus teriflunomide across over 4,500 participants.

Research presented at the European Society of Cardiology associates elevated xylitol levels with a 57 percent higher risk of cardiovascular events over six years. Xylitol is a sugar alcohol commonly used as a low-calorie sweetener in foods, drinks, chewing gum, and dental care products. These observational findings are unpeer-reviewed and do not establish causation.

Arrowhead Pharmaceuticals reported that plozasiran reduced acute pancreatitis events by 78% in patients with severe hypertriglyceridemia during Phase 3 trials. The drug lowered triglycerides by over 79% versus placebo, with high-risk patients seeing complete event elimination. The company plans to file for FDA approval by year-end 2026.

A global clinical trial published in JAMA Dermatology found that upadacitinib restored 100% scalp hair in one in five patients with alopecia areata. Approximately half of participants achieved at least 80% regrowth within 24 weeks by targeting the autoimmune response destroying hair follicles.